Why the study?
Does bivalirudin with provisional GP IIb/IIIa inhibitor improve clinical outcomes compared to UFH plus planned GP IIb/IIIa inhibitor in patients undergoing urgent or elective PCI?
Does bivalirudin with provisional GP IIb/IIIa inhibitor improve clinical outcomes compared to UFH plus planned GP IIb/IIIa inhibitor in patients undergoing urgent or elective PCI?
Bivalirudin with provisional GP IIb/IIIa inhibitor provides similar ischemic protection but significantly less bleeding compared to UFH plus planned GP IIb/IIIa inhibitor in patients undergoing urgent or elective PCI.
No takes yet. Share an insight, caveat, or question.
Noninferiority of bivalirudin for ischemic events in PCI supports consideration; leaves open bleeding comparisons versus contemporary regimens.
Maroo et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: